title: Renal sympathetic denervation for treatment of patients with heart failure: summary of the available evidence.
abstract: Heart failure syndrome results from compensatory mechanisms that operate to restore - back to normal - the systemic perfusion pressure. Sympathetic overactivity plays a pivotal role in heart failure; norepinephrine contributes to maintenance of the systemic blood pressure and increasing preload. Cardiac norepinephrine spillover increases in patients with heart failure; norepinephrine exerts direct toxicity on cardiac myocytes resulting in a decrease of synthetic activity and/or viability. Importantly, cardiac norepinephrine spillover is a powerful predictor of mortality in patients with moderate to severe HF. This provided the rationale for trials that demonstrated survival benefit associated with the use of beta adrenergic blockers in heart failure with reduced ejection fraction. Nevertheless, the MOXCON trial demonstrated that rapid uptitration of moxonidine (inhibitor of central sympathetic outflow) in patients with heart failure was associated with excess mortality and morbidity, despite reduction of plasma norepinephrine. Interestingly, renal norepinephrine spillover was the only independent predictor of adverse outcome in patients with heart failure, in multivariable analysis. Recently, renal sympathetic denervation has emerged as a novel approach for control of blood pressure in patients with treatment-resistant hypertension. This article summarizes the available evidence for the effect of renal sympathetic denervation in the setting of heart failure. Key messages Experimental studies supported a beneficial effect of renal sympathetic denervation in heart failure with reduced ejection fraction. Clinical studies demonstrated improvement of symptoms, and left ventricular function. In heart failure and preserved ejection fraction, renal sympathetic denervation is associated with improvement of surrogate endpoints.
authors.affiliation: a Heart Center, Satakunta Central Hospital , Pori , Finland.
authors.forename: Wail
authors.initials: W
authors.lastname: Nammas
authors.affiliation: b Department of Cardiology , Vaasa Central Hospital , Vaasa , Finland.
authors.forename: Juhani
authors.initials: J
authors.lastname: Koistinen
authors.affiliation: a Heart Center, Satakunta Central Hospital , Pori , Finland.
authors.forename: Tuomas
authors.initials: T
authors.lastname: Paana
authors.affiliation: a Heart Center, Satakunta Central Hospital , Pori , Finland.
authors.forename: Pasi P
authors.initials: PP
authors.lastname: Karjalainen
mesh_terms: D001794:Blood Pressure; D006333:Heart Failure / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007668:Kidney / Q000294:innervation* / Q000378:metabolism / Q000601:surgery; D009638:Norepinephrine / Q000378:metabolism; D013318:Stroke Volume; D013562:Sympathectomy / Q000379:methods*; D016277:Ventricular Function, Left
chemical_list: D009638:Norepinephrine
keywords: Renal sympathetic denervation; heart failure; left ventricular function